Join our daily newsletter At The Bell to receive exclusive market insights
Argenica Therapeutics (ASX:AGN) has achieved another important step in the progression of its Phase 2 trial to assess drug candidate ARG007 for the treatment of acute ischaemic stroke (AIS), with the last of 92 patients dosed.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
All patients had been confirmed as having had large vessel occlusion strokes and undergoing an endovascular thrombectomy procedure to remove the clot. Of these, half received an intravenous infusion of a saline placebo, while the other half received an intravenous infusion of ARG-007.
Until the last patient has their follow-up functional assessment – 90 days post-stroke – the trial will remain ‘blind,’ meaning none of the people involved in dosing or follow-up assessments will be told what treatment each patient received.
Once this final functional assessment is complete, data will be unblinded and analysed to assess the trial’s ability to meet its endpoints.
Argenica anticipates the release of its topline data in Q3 calendar year 2025.
More market news
Kowtow: “Biggest day in financial history” on Trump’s tariffs retreat
Meet GeoGeorge: The HotCopper poster so accurate he got hired as an analyst
The first endpoint for the ongoing tests involves the assessment of the drug candidate’s safety, when issued in one dose to a person with acute ischaemic stroke – examining mortality rate, incidence of serious adverse events, and incidence of symptomatic intracranial haemorrhage.
Additionally, the company will look at the effect of ARG-007 on reducing infarct volume in participants with acute ischaemic stroke.
AGN has been trading at 67 cents early on Friday morning.
Join the discussion: See what HotCopper users are saying about Argenica Therapeutics and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
